Neurophysiological mechanisms 0f Alzheimer's disease comprehensive review

Abstract

Alzheimer's disease is an incurable brain disease describe by a gradual and advanced decline in brain function in older adults.The disease process begins years before symptoms appear, which can make most treatments less effective. Alzheimer's disease (AD) biomarkers that are currently recognised and used primarily reflect the molecular and structural alterations in the brain that are linked to AD. They can be change in healthy people and frequently do not accurately reflect the degree of cognitive and functional deficits in influenced subjects, despite the fact that they are essential for identefying disease specific neuropathology and have no strong correlation with the way dementia manifests clinically. When clearance mechanisms fail, Amyloid-beta is generated when the amyloid protein (APP) is cleaved by (β , γ) secretase enzymes, leading to the buildup 0f insoluble peptide aggregates in the extracellular space. These clusters create amyloid plaques, which have direct neurotoxic effects, interfere with synaptic transmission, and cause neuroinflammation. At the same time, neurones experience pathological hyperphosphorylation of the microtubule-associated protein tau, which causes it to separate from microtubules and then aggregate into intracellular neurofibrillary tangles. Axonal transport is hampered by this process, which also destabilises the cytoskeletal structure. Amyloid-beta extracellular toxicity and tau pathology-induced intracellular dysfunction work together to cause progressive neuronal degeneration, which eventually results in Alzheimer's disease symptoms. Damaged mitochondria interfere with nerve cell communication and increase the buildup of tau and amyloid-beta proteins, two important characteristics of Alzheimer's disaese. This review's objective is to better diagnose Alzheimer's disease (AD), comprehend its aetiology and natural course, and conduct research.